Chronically elevated energy expenditure without a corresponding increase in energy intake leads to wasting and death. Almost all species in the wild, and the great majority of humans, struggle with such negative energy balance in their daily battle for survival. In sharp contrast, however, developed societies are threatened by the exact opposite: chronically elevated energy intake without the respective increase in energy expenditure. This leads to obesity and diabetes, as well as a variety of lifethreatening consequences of such diseases, such as cancer and cardiovascular disease (Eckel 1997; Calle and others 2003) . Although it appears intuitively obvious that in the majority of cases, positive energy balance should be corrected by changes in lifestyle and/or diet, the impressive dynamics of the increasing obesity prevalence (Flegal and others 2002) certainly suggest that in modern industrialized civilizations, an efficient and safe pharmacological approach to the treatment of obesity would be useful. In light of this, it is not surprising that within the past few decades, increasing attention has been paid to central and peripheral regulatory components of energy metabolism to develop pharmacological modulators of appetite and energy expenditure. What appears to be clear at this point is that it is quintessential that we gain a clearer understanding of how the brain manages (or fails to manage) the regulation of energy intake (feeding) and expenditure in the face of changing peripheral needs to develop successful strategies for triggering adequate energy balance in patients. This review is intended to give an overview of the known physiological processes of the brain that integrate a variety of afferent signals that reflect energy requirements and in turn respond with appropriate alterations in appetite, metabolism, and behavior.
Afferent Signals of the Brain in the Regulation of Energy Homeostasis
The brain plays a critical role in the regulation of energy homeostasis. Central nervous system circuits assess and integrate peripheral metabolic, endocrine, and neuronal signals that reflect current energy status, to then orchestrate a modulating influence on both behavioral patterns and peripheral metabolism according to acute and chronic requirements (Spiegelman and Flier 2001) .
The route of communication between the periphery and brain regarding information pertinent to energy homeostasis is predominantly via the circulation. Humoral signals reflecting the metabolic state arise from different peripheral tissues, including the white adipose tissue, gastrointestinal tract, thyroid, adrenals, muscle, and reproductive organs (Bray 2000; Havel 2001 ). Secreted in accordance to an animal's current state of metabolism and energy homeostasis under physiological circumstances, these hormones convey information to various areas of the brain. See Table 1 for peripheral hormones and their effects on food intake and energy expenditure.
One of the first hormones to be recognized as a signal from the periphery involved in metabolism regulation is the gastrointestinal hormone, cholecystokinin (CCK), which was first discovered in 1973. Peripherally released CCK acts centrally and initiates an acute negative energy balance (i.e., cessation of food intake) via pathways predominantly localized in the brainstem. CCK is Brain Circuits Regulating Energy Homeostasis TAMAS L. HORVATH, SABRINA DIANO, and MATTHIAS TSCHÖP For decades, increasingly sophisticated methods have been designed to address the problem of the involvement of the brain in the physiology of energy homeostasis and the pathogenesis of obesity. A vast number of experimental observations have been made from novel genetic and physiologic approaches that allowed the identification of metabolic hormones and their relationship to key peptidergic systems in the brain. Although the central integration of afferent signals reflecting acute and chronic energy requirements is becoming clearer, the blueprint of the central regulation of energy expenditure is not known. This review offers a look at central neuronal circuitries that are implicated in metabolism regulation and strongly suggests that without a blueprint, attempts to intervene and control energy balance will remain futile. NEURO-SCIENTIST 10(3): 235-246, 2004 . DOI: 10.1177 The authors' work on the study of hypothalamic circuitry and regulation of energy balance has been supported by National Institutes of Health grants MH059847, RR014451, DK060711, DK061619 and DK051730. thought to have a physiological role in regulating meal termination. This hormone/neuropeptide had been mistaken as the missing factor in the morbidly obese, mutant ob\ob mouse (Beglinger 2002) .
The ob\ob mouse phenotype results from a spontaneous mutation that, long before its identification, had already been speculated to be caused by the lack of a peripheral signal informing the brain about existing energy stores (Coleman 1978) . Brilliant physiological parabiosis experiments connecting the circulation of ob\ob mice with that of their genetically normal littermates yielded the proof of this concept (Coleman 1978) . Positional cloning of the ob gene in 1994 finally led to the discovery of the proteohormone leptin that is predominantly produced by fat cells (Friedman 2002) . Leptin is expressed according to the size of fat stores, and its administration induces a negative energy balance mediated by neuronal structures in the hypothalamus and brainstem. Leptin's role in signaling the brain about chronic changes in energy status is completed by insulin that conveys additional information about long-term changes of peripheral metabolism to the brain. Centrally administered insulin triggers a negative energy balance, whereas neuron-specific deletion of its receptor causes obesity (Niswender and Schwartz 2003) .
Peripheral hormones that reflect caloric intake and acute nutritional requirements also signal to the brain. One of these factors, PYY , a gut hormone that is secreted in response to ingestion of food and is thought to specifically act via hypothalamic Y2 receptors, acutely induces a negative energy balance (Berglund and others 2003) . Although not without controversy, PYY has, so far, offered the only intervention that reduces food intake of healthy (Batterham and others 2002) as well as obese humans (Batterham and others 2003) without a subsequent rebound in caloric intake.
To date, there is only one peripheral hormone that promotes feeding and suppresses energy expenditure. This is the gastroenteric peptide ghrelin, which apparently counterbalances energy homeostasis in opposition to the multiple anorectic signals described above (Horvath and others 2001) . Ghrelin, which predominantly targets the same neuronal structures where leptin and PYY exert their actions, induces a positive energy balance resulting in increased adiposity. Because ghrelin is secreted in response to caloric restriction and its expression and secretion are rapidly suppressed by food intake, a physiological role for ghrelin in meal initiation as the endogenous "hunger hormone" has been proposed (Cummings and Shannon 2003) .
Additional gastrointestinal hormones have been identified as afferent signals that are involved in energy balance regulation, but either their exact mechanism of action is not yet understood or their physiological role is still unclear. For example, intestinal glucagon-like peptide 1 (GLP-1) decreases appetite and food intake in rodents, but GLP-1 induces taste aversion that might be the mechanism of action of this peripheral signal to affect food intake leading to a negative energy balance (Larsen and others 2002) . Also, deletion of receptors for glucose-dependent insulinotropic polypeptide protects against obesity, whereas fat-cell and muscle-derived interleukin 6 is a cytokine that centrally induces a negative energy balance (Febbraio and Pedersen 2002) .
Hormones secreted by other endocrine glands, although largely neglected as afferent signals conveying peripheral metabolic states, energy stores, or nutritional requirements to the brain, play important roles as well in the complex networks governing appetite and body weight (Pasquali and others 2001) . For example, central administration of corticosteroids induces appetite and increases fat mass (Jeanrenaud and Rohner-Jeanrenaud 2000) . Although the negative energy balance induced by thyroid hormones is mainly attributed to their multiple peripheral effects, T4 as well as T3 receptors are also localized in the brain, where they serve as important feedback targets (Kalra and others 1999) . The same feedback principle exists for hormones of the somatotropic axis such as growth hormone and insulin-like growth factor I (IGF-I) (Pasquali and others 2001) . Gonadal steroids, including estradiol and testosterone, have also been long known to reduce appetite, increase energy expenditure, and decrease adiposity (Wade 1986) . It is yet to be deciphered precisely how the various peripheral hormones act-alone and/or in concert in the central regulation of energy balance.
Circulating levels of essential metabolic substrates also add to the integrated signal emerging from the periphery: Glucose and free fatty acids directly inform centrally located sensors about the current state of carbohydrate and lipid metabolism (Mobbs and others 2001) . Regarding free fatty acids, it is intriguing to note that one of the intracellular molecular mechanisms that are driven by these circulating metabolic signals, the one related to mitochondrial uncoupling, is readily present in hypothalamic networks of metabolism regulation: Mitochondrial uncoupling protein 2 (UCP2) is robustly expressed in hypothalamic neurons, including components of the melanocortin system (Horvath, Warden, and others 1999) . Because UCP2 was expressed in axons and axon terminals, it may be that circulating free fatty acids could serve as signals that synchronize the activity of the various peptidergic networks in the minute-by-minute regulation of energy homeostasis (Horvath, Warden, and others 1999) . In addition to circulating signals, neuronal projections from the periphery also provide information about energy homeostasis to the brain. Satiety information generated during the course of a meal is largely conveyed to the brain stem by means of afferent fibers of the vagus nerve and by afferents passing through the spinal cord from the upper gastrointestinal tract. This information mainly converges in the nucleus tractus solitarius, an area in the caudal brain stem that integrates sensory information from the gastrointestinal tract and abdominal viscera, as well as taste information from the oral cavity (Berthoud 2002; Grill and Kaplan 2002) .
The Neuroanatomy of the Brain Center of Energy Homeostasis
Information processing is via neurons in the brain. The signaling flow within the brain that underlies metabolism regulation is a highly complex process and is based on neuronal interactions. Neurons interact with each other by synapses that are established between axon terminals and dendritic or perikaryal membranes. The information transmission in synapses occurs either electrically, chemically by the release of neurotransmitters or modulators from synaptic vesicles of the axon terminal (neurotransmitters and neuromodulators), or by release of gaseous substances such as nitric oxide or carbon monoxide. In most cases, neurons have the capability to signal by all three means of synaptic transmission. However, one mode of transmission might dominate depending on the action potential as well as on substances that may directly signal to the axon terminal from the extracellular space (other neuromodulators released by nearby axons or available by volume transmission, extracellular anion and cation concentrations as well as substances released to the extracellular space by paracrine or endocrine processes). The specificity of signal transduction is ensured by the appropriate wiring of connectivity within a given network and by the availability of receptors at the right sites for released neurotransmitters or neuromodulators as well as for peripheral metabolic hormones. Although emerging data clearly suggest that glial cells also play a pivotal role in allowing normal neuronal activity, it is not unreasonable to suggest that neurons and their interaction are integral to the understanding of metabolism regulation. The fact that it is critically important that the principles of neuronal physiology are mastered (beyond the short references provided above and below) when trying to understand the regulation of metabolism is yet to be appreciated by most obesity researchers. The underlying cause of this deficit is most likely associated with the fact that the current concept of energy homeostasis reg-ulation has mainly been established by physicians and endocrinologists, whose understanding of tissue function has traditionally been more macroscopic then neurobiology demands.
It is, however, now widely accepted that without using the appropriate neurobiological premises, tools, and interpretations, we will fail to decipher the role of the brain in the regulation of energy balance and the etiology of obesity.
Brain areas involved in metabolism regulation (Fig. 1 ). There has always been a trend to simplify the regional contribution of brain areas to homeostatic regulation, which may have decisive advantages both from a theoretical as well as a practical perspective: It allows a relatively easy conceptualization of the involvement of brain mechanisms in the regulation of energy metabolism and has also contributed to a very rapid advancement of knowledge on the potential involvement of particular neuropeptides and their receptors in these processes (see below). On the other hand, the sharp focus, for example, by some on the hypothalamus and the arcuate nucleus in particular also holds an inherent danger, and that is "not to see the forest for the trees." It is important to remember that despite the massive amounts of data that have been generated over the past century, or even since the discovery of leptin (in 1994), and the repeated revelations of "the most important" hormone or neuropeptide, an effective pharmacotherapy for obesity is still lacking. Thus, when the brain structures (currently regarded as important) are listed below and their putative functions are described, the reader is advised to consider this information as useful but not as a rigid blueprint of metabolic regulation. Our current understanding of these circuits has been improving but is far less clear than it is for vision or hearing or basic motor functions.
Of the various brain areas, to date, the hypothalamus is considered as the main integrator and processor of peripheral metabolic information (Barsh and others 2000; Elmiquist 2000; Schwartz and others 2000; Ahima and Osei 2001; Cone and others 2001; Dhillo and Bloom 2001; Barsh and Schwartz 2002; Butler and Cone 2002; Crowley and others 2002; Cummings and Schwartz 2003; Schwartz and others 2003) . Arguably, however, the brain stem plays an equal role in these processes (Berthoud 2002; Grill and Kaplan 2002) .
Those hypothalamic nuclei that have been directly associated with metabolism regulation are (in anteroposterior direction) the paraventricular nucleus, arcuate nucleus, lateral hypothalamus-perifornical region, and the ventromedial and dorsomedial hypothalamic nuclei (Kalra and others 1999; Saper and others 2002) . Based on early degeneration studies, where specific brain areas were ablated surgically or chemically to study their physiological function, these nuclei could be divided into two groups: one that promotes positive energy balance (lateral hypothalamus-perifornical area) and another that promotes negative energy balance (ventromedial, dorsomedial, paraventricular nuclei). These nuclei are redundantly interconnected with each other; however, there is a predominance of efferent pathways in particular directions from one nucleus to others. For example, the arcuate nucleus that is situated in the mediobasal aspect of the hypothalamus adjacent to the third ventricle sends a large number of projections to the paraventricular and dorsomedial nuclei, with less impressive projections to the lateral hypothalamus-perifornical region and virtually no projections to the ventromedial nucleus. The ventromedial hypothalamus, on the other hand, projects to all of the aforementioned areas. The lat-eral hypothalamus-perifornical region projects massively to the arcuate, paraventricular, and dorsomedial nuclei with little input to the ventromedial nucleus. The paraventricular nucleus has limited projections within the hypothalamus but receives input from all of the other metabolism-related hypothalamic areas.
One school of thought suggests that the arcuate nucleus has the most potential to receive peripheral signals reflecting the metabolic state and that it houses parent cells of origin of two peptidergic systems (see below) considered the primum movens of metabolism regula- Fig. 1 . Signals, ligands, peripheral organs, and brain areas involved in the regulation of energy balance are shown in this simplified schematic overview. Peripheral factors and hormones from the adrenal glands, gonadal tissue, thyroid glands, muscle tissue, pancreas, adipose tissue, stomach, gut, and other peripheral organs are constantly signaling central circuits information about acute and chronic energy balance and metabolic homeostasis. Areas in the brain that have been identified as very likely to be involved in the central processing of this afferent information as well as in the continuous adjustment of an appropriate efferent response are the nucleus of the solitary tract (NTS), the lateral parabrachial nucleus (LPB), and other areas in the brain stem region as well as the arcuate nucleus (ARC), the ventromedial hypothalamus (VMH), the dorsomedial hypothalamus (DMH), the paraventricular nucleus (PVN), and the lateral hypothalamus (LH). Communication between these neuronal circuits relies on generation and release of neurotransmitters and neuropeptides, some of which are currently regarded as likely to be involved in energy balance control. Although expression of the potent orexigenic agouti-related protein (AgRP) is strictly limited to the ARC, the similarly strong appetite-promoting neuropeptide Y (NPY) is expressed in numerous brain areas involved in the regulation of body weight. The exact anatomical and functional blueprint of the projections between these agents and other neuropeptides and neurotransmitters regulating energy homeostasis such as cocaine amphetamine regulated transcript (CART), melanin-concentrating hormone (MCH), thyroid hormone releasing hormone (TRH), corticotropin-releasing hormone (CRH), oxytocin (OXY), or vasopressin (AVP) still remains at large. Even less known is the role of the visual, olfactory, or circadian input, to name just a few that might in part be mediated through specific neuronal circuits in brain areas such as the suprachiasmatic nucleus (SCn) or the supraventicular zone (SPZ).
tion. In support of this "primary sensory" function ascribed to the arcuate nucleus are the following facts: The arcuate nucleus is located most ventrally in the diencephalon where blood vessels bifurcate from the circle of Willis; this region is intimately associated with an area that is not protected by the blood-brain barrier, and thus metabolic hormones, such as leptin or ghrelin, may easily exert effects on arcuate nucleus neurons (Fig. 1) . From here, arcuate efferents relay information to target sites, such as the dorsomedial and paraventricular nuclei. Although this is a tempting and likely scenario, to date, there is no conclusive evidence demonstrating that the arcuate nucleus itself is not protected by the blood-brain barrier or that other hypothalamic areas, such as the lateral hypothalamus-perifornical area, are not direct targets of peripheral hormones. The arcuate nucleus contains two key peptidergic systems, the neuropeptide Y (NPY)/agouti-related protein (AgRP)-producing cells and their counterpart, the pro-opiomelanocortin (POMC)-producing cells. The interplay between these two neuronal subpopulations (the so-called melanocortin signaling system; see below for further details) is believed to be essential for the regulation of both food intake and energy expenditure. However, surgical ablation of the arcuate nucleus does not cause any drastic alteration in food intake or metabolism in general. Although it can be argued that removing equal amounts of orexigenic promoter (NPY-AgRP system) and blocker (POMC) should give a net result of "no change," removal of the putatively essential sensor for afferent signals reflecting energy balance with these positive and negative charges should collapse the entire system. Further evidence that undermines the significance of the arcuate nucleus in feeding behavior is the finding that in the first 3 weeks of postnatal development of rats, the efferents of the arcuate nucleus peptide systems are not yet developed; however, the feeding behavior of the animals is normal from the day of birth.
It is also important to consider that because of the essentialness of food intake for life, the systems examined here are likely to have tremendous redundancy. If this is the case, then it is unreasonable to anticipate that a "magic pill" that targets one particular aspect of this system will deliver long-term answers for obesity (Crowley and others 2002) .
Recently evolving studies indicate that both sensory and integrative functions are distributed across the basal forebrain as well as the caudal brain stem. A strong presence of leptin and insulin receptors, glucose-sensing mechanisms, and neuropeptide mediators in the brain stem suggests its pivotal role in orchestrating energy balance regulation, whereas a physiological relevance is suggested by the demonstration that similar effects can be triggered independently by stimulation of respective forebrain and brain stem subpopulations of the same receptors (Grill and Kaplan 2002) . Furthermore, decerebrate and neurologically intact rats show similar responses to taste stimuli and are similarly sensitive to inhibitory feedback from the gastrointestinal tract, indi-cating that the caudal brain stem is sufficient to mediate ingestive responses. In addition, hypothalamic neuroendocrine responses to fasting depend on pathways ascending from the brain stem. In short, this suggests that control mechanisms endemic to the hypothalamus and brain stem drive their unique effector systems on the basis of local interoceptive and, in the case of the brain stem, visceral afferent inputs and that a set of uni-and bidirectional interactions between these structures coordinates adaptive neuroendocrine, autonomic, and behavioral responses to changes in the metabolic state (Grill and Kaplan 2002) .
Of course, there are other brain areas besides the hypothalamus and brain stem that play important roles in feeding behavior. For example, the exertion of appropriate motor function is critical to gather food as well as to appropriately process ingested nutrients. Thus, both the motor cortex and mechanisms related to the motor system, including the interaction between the basal ganglia and substantia nigra dopamine cells, need to be considered. Similarly, motivational components of eating are also important elements of overall energy balance regulation, and these are likely to be associated with neuronal processes in the nucleus accumbens (Berthoud 2002) .
The debate over the neuronal blueprint of metabolism regulation is likely to continue, and further scientific progress is necessary to elucidate brain circuitry governing energy balance to a point where useful therapeutic approaches become feasible. However, there are concepts regarding other aspects of these regulatory processes that are much better understood at this point. These concepts have their basis in the understanding of the importance of peptides and classical neurotransmitters in the central regulation of metabolism. Table  2 for summary.) The past few decades have provided overwhelming evidence that the principle signaling modality within brain centers of energy balance regulation is via chemical synapses. As eluded to above, chemical neurotransmission uses neurotransmitters and neuropeptides released from synaptic vesicles of axon terminals and their respective receptors located on the postsynaptic membrane or membranes of adjacent axon terminals. Studies indicate that the central regulation of feeding behavior and energy expenditure relies on the appropriate interaction between particular neuropeptides. Therefore, those key hypothalamic neuropeptide systems that have been most closely associated with metabolism regulation are summarized below, but those that are involved to a lesser extent will not be mentioned. Detailed and thorough descriptions of these peptides and their functionality can be found in elaborate reviews (Kalra and others 1999; Barsh and others 2000; Elmquist 2000; Lowell and Spiegelman 2000; Schwartz and others 2000; Ahima and Osei 2001; Cone and others 2001; Dhillo and Bloom 2001; Spiegelman and Flier 2001; Barsh and Schwartz 2002; Berthoud 2002; Butler and Cone 2002; Crowley and others 2002; Grill and Kaplan 2002; Cummings and Schwartz 2003; Schwartz and others 2003) .
Neurotransmitters and neuropeptides in hypothalamic circuits involved in metabolism regulation. (See

Orexigenic Peptides
NPY NPY, a 36-amino acid peptide, is one of the most abundant and widely distributed neuropeptides within the nervous system and is one of the most potent stimulators of feeding. NPY administered repeatedly into the hypothalamus induces obesity accompanied by hyperphagia, decreased thermogenesis in brown adipose tissue, hyperinsulinemia, hypercorticosteronemia, reduced plasma testosterone levels, and insulin resistance in skeletal tissues. All of these adipogenic neuroendocrine and metabolic effects of central NPY administration persist when the NPY-induced hyperphagia is prevented by pair feeding, demonstrating that hyperphagia is not the only mechanism by which central NPY increases adiposity. The levels of NPY mRNA in the arcuate nucleus respond to changes in energy status. For example, they are increased during fasting and chronically upregulated in many rodent obesity syndromes, for example, the ob/ob mouse. At least five distinct receptors (Y1, Y2, Y4, Y5, and Y6), all belonging to the G-protein-coupled receptor superfamily, mediate the actions of NPY (Kalra and others 1999; Berglund and others 2003) .
AgRP
AgRP is a neuropeptide produced in arcuate nucleus NPY neurons. It is an endogenous ligand of melanocortin receptor subtypes, and upon binding to these receptors, it antagonizes (or acts as an inverse agonist on) the effect of other ligands of these receptors, including α-melanocyte stimulating hormone (α-MSH). α-MSH is one of the most potent anorexigenic brain signals (see below for further details on this mechanism) (Kalra and others 1999; Barsh and Schwartz 2002; Butler and Cone 2002) .
Endogenous Opioid Peptides
It has been long known that opiates promote phagia. The single-copy POMC gene encodes the POMC precursor PP, which yields the opioid β-endorphin (β-END), and the nonopioid peptides, ACTH and α-MSH. Within the hypothalamus, POMC neurons, localized exclusively in the arcuate nucleus, innervate the paraventricular and dorsomedial nuclei, as well as other areas of the hypothalamus, where microinjection of β-END and opiate agonists that bind to the m-receptor subtype stimulate feeding. Neurons producing the two pentapeptides, methionine-enkephalin (met-ENK) and leucineenkephalin (leu-ENK), are more widely distributed in the hypothalamus, and discrete populations of leu-ENKor met-ENK-immunopositive perikarya have been visualized in feeding-relevant sites, such as the arcuate, ventromedial, dorsomedial, and paraventricular nuclei, sites that are also richly innervated by ENK-immunopositive fibers. Central injection of the third hypothalamic opioid, dynorphin A(1-17), derived from the precursor prodynorphin, stimulated feeding by activating the k-opiate receptor subtype. Dynorphin-producing cells are also found in various regions of the hypothalamus, including the arcuate and paraventricular nuclei. A critical evaluation of food intake induced by various opioid compounds showed that opioid-evoked feeding is generally short-lived and relatively modest (Grill and Kaplan 2002; Yeomans and Gray 2002) .
Endocannabinoids
The recent discovery of cannabinoid receptors and their endogenous ligands (endocannabinoids) within the central nervous system has implicated a role for endocannabinoids in the regulation of energy balance, suggesting that an endocannabinoid tone could play a key role in the neurochemical regulation of appetite (Horvath 2003) . The effects of endocannabinoids on appetite may be explained by the expression of the ligands and their receptor (CB1) in the hypothalamus as well as in other feeding-associated brain regions such as the limbic forebrain, which are thought to be mainly involved in reward processes that mediate, for instance, the incentive value of food. Acting in brain regions such as the nucleus accumbens and the hippocampus, endocannabinoids may particularly drive appetite for palatable food, and the interactions of the endocannabinoid system with other pathways, such as the opioid system, may partially explain its involvement in reward processes. Moreover, the central levels of endocannabinoids are modified by acute peripheral energy balance changes and, in hypothalamic endocannabinoids, are expressed under direct negative control by leptin. Consistent with enhanced endocannabinoid signaling in the hypothalamus of mutant rodents with defective leptin signaling, blockade of CB1 leads to a decreased food intake in these animal models, strongly suggesting that the endocannabinoid system might play an important endogenous role in the hypothalamic regulation of energy homeostasis. Endocannabinoids have recently been classified as neuromodulators belonging to the family of the appetite-stimulating neuromediators (Cota and others 2003) .
Melanin-Concentrating Hormone
A population of neurons in the zona incerta and lateral hypothalamus produce the 19-amino acid peptide, melanin-concentrating hormone (MCH), and project into several hypothalamic, limbic, and cortical areas. Qu and others reported potentiation of ongoing nocturnal feeding for 4 to 6 h by MCH administration at the onset of the dark phase. Further studies revealed several parallels between MCH and NPY systems in the hypothalamus. MCH augmented ongoing feeding, fasting stimulated MCH gene expression in the hypothalamus, and MCH mRNA was elevated in genetically obese ob/ob mice. MCH also stimulated the hypothalamopituitaryadrenal axis. These similarities raised the intriguing possibility that MCH may be an additional orexigenic signal that either independently or together with NPY participates in the hypothalamic regulation of energy homeostasis. However, this assumption must await further experimental validation because potent anorectic effects on nighttime food intake and suppression of body weight by extremely low doses of MCH have been reported. Similarly, microinjection of MCH into the zona incertalateral hypothalamic region reduced feeding. Orexigenic effects of MCH in rats have also been observed, but relative to NPY, MCH-induced feeding seems less impressive and of shorter duration. Furthermore, despite the acute stimulatory effects of MCH, cumulative 24-h intake was unaffected, and repeated daily injections stimulated food intake for a few days without changing the body weight. Interestingly, small lesions in the ventromedial nucleus that stimulated MCH gene expression in the hypothalamus failed to evoke hyperphagia (Kalra and others 1999; Boutin and others 2002) .
Hypocretins/Orexins
Hypocretins 1 and 2 were localized in clusters in the dorsal and lateral hypothalamic area and perifonical hypothalamus (de Lecea and others 1998; Sakurai and others 1998) . Immunoreactive axons emanating from these cells innervated various forebrain structures anteriorly, such as the arcuate nucleus, paraventricular nucleus of the thalamus, preoptic area, and the septal nuclei, and caudally-the locus coeruleus and a few other sites in the brainstem (Horvath, Diano, and others 1999; Horvath, Peyron, and others 1999) . Intracerebroventricular injections of hypocretin 1 (orexin A) and hypocretin 2 (orexin B) stimulated feeding in a dose-related fashion with orexin A significantly more effective than orexin B, possibly due to activation of both orexin A and orexin B receptor subtypes. Orexin was found to be less effective than NPY in stimulating food intake, and as with NPY and MCH, fasting upregulated orexin gene expression in the hypothalamus. A comparative evaluation of the potency of orexins with other orexigenic signals so far examined indicates that high doses of intracerebroventricular injections of orexins rather than of other signals (galanin, MCH, or GABA) were needed to elicit significant stimulation of feeding. Using positional cloning in a canine model of narcolepsy and mouse gene knockouts, hypocretin/orexin ligand and hypocretin/orexin receptor genes have recently been identified as key elements within the pathogenesis of narcolepsy. Mutations in hypocretin-related genes are rare in humans, but hypocretin-ligand deficiency is found in many cases of narcolepsy. Hypocretins/orexins may be involved in various hypothalamic mechanisms; a modest effect on energy homeostasis might not reveal their primary function but be secondary to their probably major role in arousal control (Chemelli and others 1999; Lin and others 1999) .
Hypothalamic Ghrelin
With respect to the role of ghrelin in the regulation of energy homeostasis, the recent finding of its localization in the hypothalamus created an interest comparable to that elicited when ghrelin was found to be localized in the stomach. A uniquely distributed hypothalamic group of mostly bipolar neurons has recently been identified as producing small amounts of ghrelin (Fig. 2) . These neurons are not co-localized with any known centrally expressed hormone or neuropeptide, but intriguingly, they do project directly to several previously identified hypothalamic appetite control centers. Furthermore, ghrelin receptor expression and binding can be localized in multiple hypothalamic areas that directly neighbor NPY, AgRP, POMC, GABA, and other neuropeptides and neurotransmitters substantially involved in appetite control. Ghrelin expression can be found in neurons situated close to, but not in contact with, those previously mentioned. These neuroanatomical findings, complemented by electrophysiological studies, provided evidence for the existence of a central circuit regulating appetite that involves ghrelin as a key modulator (Cowley and others 2003) .
Anorexigenic Signals
α-MSH
The melanocortin system is thought to be one of the most important pathways involved in the regulation of food intake, with mutations within the system found in approximately 4% of cases of genetic obesity in humans.
Melanocortins are peptides that are cleaved from the POMC precursor molecule and exert their effects by binding to members of a family of melanocortin receptors (MC1-R to MC5-R). α-MSH, one of the products of the POMC gene, acts as an endogenous agonist of the MC3-R and MC4-R, the two melanocortin receptor subtypes that are thought to be important in the regulation of food intake. The importance of the melanocortin system in the control of food intake and energy regulation was first highlighted by the hyperphagic, obese, and hyperinsulinemic phenotype of the agouti lethal yellow (A y /a) mouse. Agouti is a 131-amino acid peptide, which is secreted by dermal papilla cells during the hair growth cycle, where it normally antagonizes α-MSH binding to the MC1-R in the melanocyte. This antagonism shifts pigment production from eumelanin to phaeomelanin resulting in a subapical yellow band. Ectopic expression of agouti in the A y /a mouse results in a yellow coat color and obesity, the latter due to the agouti acting as an antagonist to α−MSH at the central MC4-R. Targeted gene deletion of the MC4-R results in a hyperphagic obese mouse similar in phenotype to the A y /a mouse.
The melanocortin system has an endogenous antagonist, AgRP, coexpressed in the same neuronal population as NPY. AgRP acts as an antagonist (or an inverse agonist) to increase food intake and decrease energy expenditure at the MC3-R and MC4-R (Zimanyi and Pelleymounter 2003) .
Corticotropin-Releasing Hormone (CRH) Family of Peptides
CRH was isolated and sequenced in 1981. It is the primary hypothalamic hormone that stimulates the release of pituitary ACTH, which in turn stimulates corticosterone secretion from the adrenal glands. CRH-producing cells involved in the regulation of the pituitary-adrenal axis are localized mainly in the pPVN. These neurons project into the external zone of the median eminence to release CRH into the hypophyseal portal system for transport to the pituitary. CRH also exerts powerful excitatory effects on arousal and locomotor activity and elicits anxiogenic-like effects in rats. Central injection of CRH produces anorexia, as evidenced by attenuation of nocturnal and fasting-induced feeding, and diminishes feeding in a number of pharmacological and behavioral paradigms designed to evaluate ingestive behavior. These diverse biological effects of CRH are exerted at specific sites in the brain. Indeed, multiple subpopulations of CRH-producing neurons, CRHimmunoreactive terminals, and high-affinity binding sites have been localized in various regions in the brain. Microinjection studies revealed that the sites of anorectic action of CRH lies within the paraventricular nucleus, possibly mediated by CRH R1 or CRH R2 receptor types. The fact that intraventricular injection or microinjection of CRH into the paraventricular nucleus, and not elsewhere in the hypothalamus, inhibited NPY-induced feeding further strengthened the notion that CRH, if released locally into the paraventricular nucleus, may tonically restrain the action of endogenous orexigenic signals (Richard and others 2002) .
Urocortin
Urocortin, a recently described member of the CRH family with a 45% sequence homology with CRH, has been shown to be more potent than CRH in suppressing both nocturnal and fasting-induced feeding. The reduction in nocturnal feeding by urocortin was found to be due to a decrease in meal size and not frequency of meal bouts. This observation questions the physiological significance of this anorexic peptide in nocturnal feeding marked by a robust increase in both meal size and frequency. The topographies of urocortin and CRHexpressing cells in the rat brain are quite different and interesting. Urocortin-expressing cells are found in the Edinger-Westphal nucleus, the lateral superior olive, the lateral hypothalamus, and supraoptic nucleus but not in the paraventricular nucleus. The higher anorectic potency of urocortin has been attributed to a relatively higher affinity of urocortin for CRH R2 and its splice variant CRH R2a. Although urocortin immunoreactive nerve fibers innervate the lateral septum, ventromedial hypo- Ghrelin-producing neurons were detected with a unique hypothalamic distribution. The background image is a color darkfield image of ghrelin neurons and processes (yellow) in the hypothalamus. Most of the cells are located in cell-sparse areas between classical hypothalamic nuclei. The overlain schematic drawing illustrates that ghrelin neurons synapse on other hypothalamic cell bodies that are key in metabolism regulation, including neuropeptide Y (NPY) (red), pro-opiomelanocortin (POMC) (green), and corticotropin-releasing factor (CRF) (orange) neurons. Inserts show that these synaptic interactions predict the electrophysiological effect of ghrelin on these postsynaptic targets. In accordance with ghrelins' action on metabolism, ghrelin activates NPY neurons, inhibits POMC cells, and disinhibits CRF neurons.
Volume 10, Number 3, 2004   THE NEUROSCIENTIST  243 thalamus, and medial amygdaloid nucleus, urocortin microinjections into the ventromedial hypothalamus but not into the paraventricular nucleus inhibited feeding (Richard and others 2002) .
Neurotensin (NT)
NT, isolated and characterized in the early 1970s, inhibits spontaneous and norepinephrine-induced feeding in rats, and there is evidence that NT and dopamine act synergistically to inhibit feeding. The neuroanatomical mapping of NT pathways in the rat hypothalamus is consistent with the existence of anorexigenic pathways. Within the hypothalamus, NT-like immunopositive neurons exist in several distinct nuclei. Notable among these are the subset of NT-producing neurons in the arcuate, paraventricular, and dorsomedial nuclei. In addition, these and neighboring sites are richly innervated by NTimmunopositive fibers. Interestingly, recent studies showed that a subset of NT-positive neurons in the dorsomedial nucleus projects into both the pPVN and mPVN, sites where microinjection of NT inhibited spontaneous feeding. In addition, consistent with a reciprocal interaction between NPY and NT that underlies hyperphagia in rodents, it has also been reported that ob/ob mice exhibited decreased hypothalamic NT mRNA and peptide levels in association with enhanced NPY levels and gene expression (Kitabgi 2002) .
GLP-1
GLP-1 (7-36) amide is processed from proglucagon in intestinal L cells and is considered to be a hormone related to the glucagon/secretin family of peptides. Like several other gastrointestinal peptides, GLP-1 has been found in various forebrain and hypothalamic regions that correspond with GLP-1-binding sites in the arcuate and paraventricular nuclei. An extensive hypothalamic innervation by GLP-1-immunoreactive fibers appears to emanate from a single population of non-catecholamineproducing neurons in the caudal portion of the nucleus of the solitary tract. Intraventricular administration of GLP-1 inhibited food intake in fasted rats, a response blocked by the concurrent administration of exendin (9-39), a GLP-1-receptor antagonist. A physiological role of GLP-1 as an anorectic or satiety factor was suggested by the observations that exendin stimulated feeding in satiated rats during the lights-on period and daily injections of exendin augmented food intake and body weight. Evidence suggests that one of the sites of GLP-1 action may be the paraventricular nucleus where GLP-1-immunoreactive fibers terminate and where exendin blocked GLP-1-induced activation of c-FOS. The anorectic effects of GLP-1 may be mediated through NPY signaling because GLP-1 inhibited, and exendin (9-39) augmented, NPY-induced feeding. The suppression of feeding by GLP-1 likely involves inhibition of the postsynaptic signaling initiated by NPY in the paraventricular nucleus and not by suppression of NPY synthesis in the arcuate nucleus. That GLP-1 may be an endogenous anorectic signal was indicated by the report that attenuation of feeding by GLP-1 was not due to conditioned taste aversion (Meier and others 2002) , whereas others reported opposite observations (Thiele and others 1997) .
Cocaine and Amphetamine-Regulated Transcript (CART)
CART was localized in the rat brain and shown to be distributed in feeding-related sites in the hypothalamus. Intraventricular administration of CART inhibited nocturnal as well as fasting-induced feeding in mice and rats. An extensive series of investigations by two laboratories provided strong evidence that CART may be a physiologically relevant anorectic signal. This view is supported by the following evidence: 1) Administration of antiserum against CART, to neutralize the anorectic impact, increased nighttime feeding. 2) CART mRNA was localized in the arcuate nucleus, paraventricular nucleus, supraoptic nucleus, rostral part of the ventromedial hypothalamus, anterior paraventricular nucleus of the hypothalamus, and several other nuclei in the diencephalon. Fiber projections from these CARTproducing cells were located in a large number of hypothalamic nuclei.
3) The expression of CART mRNA in response to fasting decreased in the arcuate nucleus and dorsomedial hypothalamus in normal rats. 4) In genetically obese rodents, Zucker (fa/fa) rats, and ob/ob mice, CART gene expression in the arcuate nucleus and dorsomedial hypothalamus was decreased relative to wildtype controls. 5) Leptin administration to ob/ob mice, which lack leptin, increased CART mRNA in the arcuate nucleus to the range seen in wild-type lean control mice. This response was associated with a decrease in food intake in the ob/ob mice. 6) Interestingly, CART administration markedly inhibited the NPY-induced feeding in fasted and normal rats. Although these results suggested an inhibitory action of CART exerted at postsynaptic levels, immunocytochemical studies showed a close apposition of NPY-containing terminals with the perikarya of CART peptide-immunoreactive neurons in the pPVN, possibly representing an NPY→CART communication line. This observation is highly suggestive of a regulatory role of NPY on CART output, in a fashion similar to NPY→galanin, NPY→POMC, NPY→orexin signaling. Thus, CART-containing neurons appear to represent one of the most powerful physiological anorexic signaling pathways (Larsen and others 2002) .
Efferent Signals of the Brain in the Regulation of Energy Homeostasis
In response to varying but simultaneously changing peripheral signals, central neuronal networks must be functioning in an orchestrated fashion to evoke an appropriate behavioral and endocrine efferent response.
Although it is clear that these efferent signals, including hormonal, behavioral, and neuronal outputs, induce changes in energy expenditure, it is still uncertain how appetite induction is triggered by hypothalamic circuits involving the arcuate nucleus and other hypothalamic centers of feeding control such as the lateral hypothalamus. The classical endocrine axes consisting of hypothalamic releasing hormones, pituitary hormones, and peripheral endocrine signals are, without exception, involved in maintaining the balance of metabolism and energy homeostasis. The activation of the hypothalamicpituitary-adrenal axis induces a positive energy balance, whereas stimulation of the hypothalamic-pituitarythyroid axis produces energy deficits by increasing the metabolic rate. In addition, the growth hormone IGF-I axis (somatotropic axis) promotes lipolysis and muscle growth; the stimulation of the hypothalamic-pituitarygonadal axis causes a negative energy balance in women and an increased ratio of muscle to fat tissue in men. Both the sympathetic and parasympathetic nervous sys-tems, however, are believed to represent the predominant mediating structures from the brain to the periphery to adjust energy balance according to acute and chronic requirements (Lowell and Spiegelman 2000; Berthoud 2002) . Nevertheless, the effector elements in food intake and energy expenditure regulation are largely unknown and will represent important targets for future research.
Synopsis
The extensive anatomical and experimental evidence clearly implies that orexigenic and anorexigenic circuits do not act individually but rather as an interconnected network to integrate peripheral and central signals for the minute-by-minute regulation of daily energy balance (see Figs. 1 and 3 ; Kalra and others 1999; Mieda and Yanagisawa 2002) . There are several further considera- Fig. 3 . Central receptors and sensors involved in the regulation of energy balance are shown in this simplified schematic overview. Peripheral factors are constantly signaling central circuits information about acute and chronic energy balance and metabolic homeostasis. Areas in the brain that have been identified as very likely to be involved in the central processing of this afferent information as well as in the continuous adjustment of an appropriate efferent response are several areas of the brain stem region as well as the arcuate nucleus (ARC), the ventromedial hypothalamus (VMH), the dorsomedial hypothalamus (DMH), the paraventricular nucleus (PVN), and the lateral hypothalamus (LH) in the hypothalamic region. Populations of neurons in these areas, which by now have been identified as likely to be involved in the central control of energy homeostasis, are carrying cannabinoid type 1 receptors (CB1R), cholecystokinin A receptors (CCKAR), dopamine receptor subtypes 1 through 5 (D1R, D2R, D3R, D4R, D5R), estrogen receptors (EstrogenR), glucagon-like peptide 1 and 2 receptors (GLP-1R, GLP-2R), glucocorticoidreceptors, glucosesensing neurons (Glucosesens), growth hormone receptors (GHR), ghrelin receptors (GHSR), insulin and leptin receptors (insulinR, leptinR), melanocortin receptor subtypes 3 and 4 (MC3R, MC4R), orexin receptor subtypes 1 and 2 (Orexin1R, Orexin2R), melanin-concentrating hormone receptors (MCHR), and neuropeptide Y receptor subtypes 1 through 4 (Y1R, Y2R, Y3R, Y4R, Y5R). It is not only very likely that many of these receptors and their ligands turn out to not play an essential role in energy balance regulation, but it can also be anticipated that these by-now identified pathways are only the "tip of the iceberg" of a much more complex system involving numerous other endocrine as well as neuronal circuits. tions that need to be included. Most of the neuromodulators described above are co-localized with one another and/or with other neurotransmitters, such as glutamate or GABA. Thus, when one neuromodulator is addressed in experimental paradigms, its effect must be placed in the context of other neuromodulators, neurotransmitters. In addition, no physiological, pharmacological, biochemical, or genetic information can be placed in "realtime" concepts without the detailed understanding of the redundant wiring of the various neuronal networks. Not only the detailed anatomy of these circuits must be assessed (which must include the detailed assessment of their synaptological interactions both at the level of electron microscopy and electrophysiology), but it must be determined whether and to what extent the circuitry is hardwired or undergoing constant change. Although we are far from having the breadth of knowledge that would allow appropriate manipulation of metabolism and related disorders, better appreciation, comprehension, and application of contemporary neurobiological advances will have a significant impact on the development of medically relevant insight into energy balance regulation.
